ABSTRACT
Objective:
This study aimed to evaluate the
efficacy of adjunct low-frequency
pulse electrical stimulation alongside
dexamethasone in the
treatment of
facial nerve paralysis and its subsequent effects on
facial nerve function and electromyographic
parameters. With the aim of addressing a
knowledge gap in the field, this
research provides valuable insights into the potential benefits of combining these
treatments and their impact on clinical outcomes,
facial nerve functionality, and electromyographic dynamics.
Methods:
A cohort of 66
patients with
facial nerve paralysis treated at our institution between April 2018 and November 2021 were randomly assigned to either an
observation (n=33) or an experimental group (n=33). The
observation group received standard
pharmacotherapy, including Western medications and Daqinjiao decoction, along with
dexamethasone. The experimental group was administered low-frequency
pulse electrical stimulation in addition to the
observation group's regimen. Outcomes assessed were
clinical efficacy,
facial nerve paralysis scoring,
facial nerve functional scoring and indices, electromyographic latency, amplitude ratios between affected and unaffected sides, as well as any adverse events.
Results:
The experimental group demonstrated a significant improvement over the
observation group in clinical
treatment outcomes,
facial nerve paralysis scores, and
facial nerve function scores (P < .05 for all). Furthermore, electromyographic
analysis revealed shorter latency periods and greater amplitude ratios in the experimental group's
facial muscles post-
treatment (P < .05). No significant difference was observed in the
incidence of adverse reactions between the two groups (P > .05).
Conclusion:
The integration of low-frequency
pulse electrical stimulation with
dexamethasone therapy significantly ameliorates the severity of
facial nerve paralysis, enhances
facial nerve function, and improves electromyographic signals in
facial muscles without increasing
adverse effects. These findings support the clinical value and
safety of this combined
treatment approach for
facial nerve paralysis, suggesting its suitability for broader clinical application. These results suggest that this combined
treatment approach holds promise for broader clinical application, potentially providing a more effective and safer
therapeutic option for
patients with
facial nerve paralysis. Implementing this approach in clinical practice may
lead to improved
treatment outcomes, better functional recovery, and enhanced
quality of life for affected individuals.